^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MUC13 (Mucin 13)

i
Other names: MUC13, Mucin 13, Cell Surface Associated, Down-Regulated In Colon Cancer 1, DRCC1, Mucin 13, Epithelial Transmembrane, Mucin-13, MUC-13, RECC
17d
Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis. (PubMed, Br J Cancer)
In conclusion, aberrant mucin signatures reflect distinct molecular pathways in (pre)malignant GIT lesions and highlight their potential utility as biomarkers and therapeutic targets. Schematic representation of the main findings regarding altered mucin signalling in several precancerous lesions (adenomatous (i.e., conventional pathway 1) and serrated polyps (i.e. pathway 2)) and small intestinal (SIA) and colorectal (CRC) adenocarcinomas and its clinicopathological significance (outcome, anatomical location (proximal/distal), molecular subtypes (MSI, (non)-mucinous).
Retrospective data • Review • Journal
|
MSI (Microsatellite instability) • MUC1 (Mucin 1) • MUC13 (Mucin 13) • MUC2 (Mucin 2) • MUC5AC (Mucin 5AC)
1m
RNA sequencing and bioinformatics analysis have identified MAST1 as a potential biomarker and therapeutic target for cervical cancer. (PubMed, Transl Cancer Res)
In vitro cell experiments showed that the knockdown of MAST1 in Hela cells reduced cell invasion ability and downregulated the p-AKT and p-P38 signaling pathways. This study contributes to a deeper understanding of the role of MAST1 in the invasion of CC, affecting the occurrence and development of malignant tumors in the cervix through the p-AKT and p-P38 classical signaling pathways, and can serve as a potential therapeutic target for patients with CC.
Journal
|
MUC13 (Mucin 13)
2ms
Integrated Multiomics Validation of Key MUC Gene Expression for the Signature Biomarker in the Pakistani Cohort. (PubMed, Biomed Res Int)
In conclusion, our findings suggest MUC3A/MUC4/MUC13/MUC16 as robust diagnostic and prognostic biomarkers and liquid biopsy as a noninvasive approach to be integrated into daily clinical practice. This analysis can also be extended to other malignancies.
Journal
|
MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated) • MUC13 (Mucin 13)
5ms
Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives. (PubMed, Biochim Biophys Acta Rev Cancer)
Therapeutic strategies targeting anoikis and NETosis, including inhibitors of integrins, EGFR, and NET components (e.g., DNase I, CXCR2 antagonists), inhibitors of autophagy (e.g., CQ, HCQ, azithromycin) are discussed. This comprehensive analysis advances understanding of CRCLM pathogenesis and provides novel perspectives for targeted interventions.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • FASN (Fatty acid synthase) • MUC13 (Mucin 13) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • GLI2 (GLI Family Zinc Finger 2) • SIRT6 (Sirtuin 6)
6ms
A multi-phase approach using supervised algorithms and clinical models to generate high-accuracy signatures for pancreatic cancer. (PubMed, Comput Biol Med)
The study successfully identified and validated a panel of biomarkers specific to pancreatic cancer, with potential applications in early diagnosis and treatment. The findings highlight the importance of multi-omics data integration in cancer research and the potential of personalized medicine in improving patient outcomes. The in-silico drug targeting analysis provides a foundation for the development of novel drugs for PanCa treatment. Hence TFF1, S100P, MUC13, and UGT1A1 showcased themselves as most promising biomarkers and novel drug targets.
Journal
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CD36 (thrombospondin receptor) • MUC13 (Mucin 13) • TFF1 (Trefoil Factor 1) • S100P (S100 calcium binding protein P)
7ms
Targeting Tumor Differentiation Grade-related Genes Prognostic Signature Including COL5A1 Based on Single-cell RNA-seq in Gastric Cancer. (PubMed, Int J Med Sci)
Finally, the hub gene COL5A1 was obviously correlated with B cells memory, dendritic cells activated, macrophages M0, macrophages M2, plasma cells, T cells follicular helper in GC. This study reveals a novel tumor differentiation grade-related genes signature, and COL5A1 represents a promising biomarker in GC.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • COL1A1 (Collagen Type I Alpha 1 Chain) • MUC13 (Mucin 13) • MAGEA3 (MAGE Family Member A3) • COL5A1 (Collagen Type V Alpha 1 Chain) • RGS2 (Regulator Of G Protein Signaling 2)
11ms
Computational discovery of co-expressed antigens as dual targeting candidates for cancer therapy through bulk, single-cell, and spatial transcriptomics. (PubMed, Bioinform Adv)
Finally, we leveraged the emerging spatial transcriptomic to validate the co-expressed pair in situ. A standalone R package (https://github.com/Bin-Chen-Lab/bsAbsFinder).
Journal • IO biomarker
|
GPC3 (Glypican 3) • MUC13 (Mucin 13)
1year
Bidirectional signals generated by Siglec-7 and its crucial ligand tri-sialylated T to escape of cancer cells from immune surveillance. (PubMed, iScience)
Mass spectrometry of the products revealed a ligand glycan, tri-sialylated T antigen. These results indicate that Siglec-7 interaction with its ligand generates bidirectional signals in NK and cancer cells, leading to the efficient escape of cancers from host immune surveillance.
Journal
|
MUC13 (Mucin 13) • PODXL (Podocalyxin)
1year
RUNX1-MUC13 Interaction Activates Wnt/β-Catenin Signaling Implications for Colorectal Cancer Metastasis. (PubMed, Int J Biol Sci)
RUNX1 promotes CRC progression by upregulating MUC13 and activating the Wnt/β-catenin pathway. This RUNX1-MUC13 axis represents a potential therapeutic target for managing CRC.
Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • MUC13 (Mucin 13)
|
RUNX1 overexpression
over1year
Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy. (PubMed, J Ovarian Res)
While traditional markers are limited by their elevated levels in non-cancerous conditions, mucins offer a new possibility for targeted treatment in ovarian cancer. This review comprehensively described the potential of mucins for the generation of ADC therapy, highlighting their importance in the quest to improve the outcome of ovarian cancer patients.
Review • Journal
|
MUC1 (Mucin 1) • MUC16 (Mucin 16, Cell Surface Associated) • MUC13 (Mucin 13)
over1year
Albumin-Based MUC13 Peptide Nanomedicine Suppresses Liver Cancer Stem Cells via JNK-ERK Signaling Pathway-Mediated Autophagy Inhibition. (PubMed, ACS Appl Mater Interfaces)
The prepared nanomedicine could inhibit LCSCs through JNK-ERK signaling pathway-mediated autophagy inhibition and exert potent antitumor effect both in vitro and in vivo. Together, this study provides a promising peptide-based nanomedicine for high-performance HCC treatment.
Journal • Cancer stem
|
MUC13 (Mucin 13)
over1year
Detection and Analysis of Antidiarrheal Genes and Immune Factors in Various Shanghai Pig Breeds. (PubMed, Biomolecules)
The IL-2 level of the AG type of the FUT1 gene was obviously higher than that of the GG type of Pudong white pigs, the IL-2 level of the AA type of the MUC4 gene was dramatically higher than that of the AG type, and the IgG level of the GG type of the MUC13 gene was apparently higher than that of the AG type. The results of this study are of great significance in guiding the antidiarrhea breeding and molecular selection of Shanghai white pigs, Fengjing pigs, Shawutou pigs, Meishan pigs and Pudong white pigs and laying the foundation for future antidiarrhea breeding of various local pig breeds in Shanghai.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MUC4 (Mucin 4, Cell Surface Associated) • MUC13 (Mucin 13) • TAP1 (Transporter 1)